Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aura Biosciences, Inc.AURA · Entity 5142 | Director · See Remarks | March 02, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aura Biosciences, Inc.
Report date March 02, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 575,815 |
Reported balance
After 2026-03-02 transaction · row 1
1 source rowRow 1 · 2026-03-02 · Grant · Acquired 166,000 · Balance 575,815 F1: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on January 15, 2027, subject to the Reporting Person's continued service as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.14 · Expires 2036-03-02 | Direct | 249,000 |
Reported balance
After 2026-03-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-02 · Grant · Acquired 249,000 · Balance 249,000 F3: The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date. |
| Common StockSEC Table I · non-derivative | IndirectBy EdIP Revocable Trust | 127,763 |
Reported balance
Holding disclosure · report date 2026-03-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 127,763 F2: The shares are held by the Elisabet de los Pinos Revocable Trust U/D/T dated April 8, 2016, of which the Reporting Person is a trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on January 15, 2027, subject to the Reporting Person's continued service as of each such vesting date.
F2: The shares are held by the Elisabet de los Pinos Revocable Trust U/D/T dated April 8, 2016, of which the Reporting Person is a trustee.
F3: The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2026 Filed Mar 3, 2026 16:06 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 249,000 | $0.00 Strike: $6.14 | $0.00 |
DisclosureSEC source: 0001193125-26-088162 · ownership.xml · derivative · entry 3 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 249,000 Underlying: Common Stock · 249,000 shares Expires 2036-03-02 F3 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 16:06 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantCommon Stock | 166,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-088162 · ownership.xml · nonDerivative · entry 1 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 575,815 F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on January 15, 2027, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| February 17, 2026 Filed Feb 17, 2026 19:46 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | SaleCommon Stock | 47,648 | $5.06 | $241,098.88 |
DisclosureSEC source: 0001193125-26-055487 · ownership.xml · nonDerivative · entry 1 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 409,815 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.04 to $5.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 20, 2026 Filed Jan 20, 2026 18:41 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | SaleCommon Stock | 16,928 | $4.86 | $82,270.08 |
DisclosureSEC source: 0001193125-26-016938 · ownership.xml · nonDerivative · entry 1 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 457,463 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.73 to $4.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 29, 2025 Filed Oct 29, 2025 17:05 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | SaleCommon Stock | 9,049 | $6.35 | $57,461.15 |
DisclosureSEC source: 0001193125-25-256619 · ownership.xml · nonDerivative · entry 1 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 474,391 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 16:05 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,948 | $0.00 Strike: $5.07 | $0.00 |
DisclosureSEC source: 0000950170-25-081615 · ownership.xml · derivative · entry 4 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,948 shares Expires 2025-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These shares were acquired and/or withheld to cover the exercise price and resulting tax obligations, as applicable, in connection with a net (cashless) exercise of stock options. The stock options subject to the net exercise were to expire June 2, 2025. These transactions were completed subsequent to the execution of a Lock-Up Agreement and the shares received are subject to the provisions of that agreement. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 16:05 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | Tax withholdingCommon Stock | 9,948 | $6.16 | $61,279.68 |
DisclosureSEC source: 0000950170-25-081615 · ownership.xml · nonDerivative · entry 2 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 483,440 F1 · kind: These shares were acquired and/or withheld to cover the exercise price and resulting tax obligations, as applicable, in connection with a net (cashless) exercise of stock options. The stock options subject to the net exercise were to expire June 2, 2025. These transactions were completed subsequent to the execution of a Lock-Up Agreement and the shares received are subject to the provisions of that agreement. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 16:05 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | Exercise / conversionCommon Stock | 10,948 | $5.07 | $55,506.36 |
DisclosureSEC source: 0000950170-25-081615 · ownership.xml · nonDerivative · entry 1 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 493,388 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These shares were acquired and/or withheld to cover the exercise price and resulting tax obligations, as applicable, in connection with a net (cashless) exercise of stock options. The stock options subject to the net exercise were to expire June 2, 2025. These transactions were completed subsequent to the execution of a Lock-Up Agreement and the shares received are subject to the provisions of that agreement. Read SEC document |
| February 18, 2025 Filed Feb 18, 2025 19:30 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | SaleCommon Stock | 20,221 | $7.75 | $156,795.66 |
DisclosureSEC source: 0000950170-25-022651 · ownership.xml · nonDerivative · entry 1 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 482,440 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.75 to $8.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 17:52 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 255,680 | $0.00 Strike: $7.68 | $0.00 |
DisclosureSEC source: 0000950170-25-013830 · ownership.xml · derivative · entry 3 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 255,680 Underlying: Common Stock · 255,680 shares Expires 2035-02-02 F4 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vest on February 3, 2026 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 17:52 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantCommon Stock | 194,320 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-013830 · ownership.xml · nonDerivative · entry 1 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 502,661 F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on February 15, 2026, subject to the Reporting Person's continued service as of each such vesting date. F2 · balance_after: On November 7, 2023, the Reporting Person filed a Form 4 which incorrectly included an additional 3,649 shares in the amount of securities beneficially owned directly after the reported transaction and excluded 3,649 shares from the amount of securities beneficially owned indirectly after the reported transaction. The Reporting Person's holdings after the transactions reported on this Form 4 reflect this correction. Read SEC document |
| January 21, 2025 Filed Jan 21, 2025 21:09 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | SaleCommon Stock | 15,955 | $7.67 | $122,381.23 |
DisclosureSEC source: 0000950170-25-007495 · ownership.xml · nonDerivative · entry 1 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 304,692 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.67 to $7.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 29, 2024 Filed Oct 29, 2024 20:28 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | SaleCommon Stock | 9,200 | $10.74 | $98,787.76 |
DisclosureSEC source: 0000950170-24-118478 · ownership.xml · nonDerivative · entry 1 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 320,647 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.61 to $10.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 18, 2024 Filed Oct 18, 2024 20:08 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | Exercise / conversionStock Option (Right to Buy) · Derivative | 24,992 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0000950170-24-115729 · ownership.xml · derivative · entry 4 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 336,171 Underlying: Common Stock · 24,992 shares Expires 2028-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 22, 2023 previously adopted by the reporting person. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| October 18, 2024 Filed Oct 18, 2024 20:08 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | SaleCommon Stock | 24,992 | $12.04 | $300,838.70 |
DisclosureSEC source: 0000950170-24-115729 · ownership.xml · nonDerivative · entry 2 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 329,847 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 22, 2023 previously adopted by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 18, 2024 Filed Oct 18, 2024 20:08 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | Exercise / conversionCommon Stock | 24,992 | $2.74 | $68,478.08 |
DisclosureSEC source: 0000950170-24-115729 · ownership.xml · nonDerivative · entry 1 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 354,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 22, 2023 previously adopted by the reporting person. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 17:08 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,474 | $0.00 Strike: $5.76 | $0.00 |
DisclosureSEC source: 0000950170-24-110933 · ownership.xml · derivative · entry 3 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,474 shares Expires 2024-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On September 27, 2024, the Reporting Person exercised long held stock options to purchase 5,474 shares of the Issuer's common stock, as they were set to expire on October 1, 2024. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 17:08 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | Exercise / conversionCommon Stock | 5,474 | $5.76 | $31,530.24 |
DisclosureSEC source: 0000950170-24-110933 · ownership.xml · nonDerivative · entry 1 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 329,847 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On September 27, 2024, the Reporting Person exercised long held stock options to purchase 5,474 shares of the Issuer's common stock, as they were set to expire on October 1, 2024. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 16:01 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 237,065 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0000950170-24-010460 · ownership.xml · derivative · entry 3 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 237,065 Underlying: Common Stock · 237,065 shares Expires 2034-01-31 F3 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2025 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 16:01 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantCommon Stock | 162,935 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-010460 · ownership.xml · nonDerivative · entry 1 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 324,373 F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on February 15, 2025, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| January 23, 2024 Filed Jan 24, 2024 16:20 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | SaleCommon Stock | 15,853 | $7.64 | $121,140.70 |
DisclosureSEC source: 0000950170-24-006988 · ownership.xml · nonDerivative · entry 1 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,438 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.64 to $7.6758, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 06, 2023 Filed Nov 7, 2023 18:19 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,800 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0000950170-23-060499 · ownership.xml · derivative · entry 4 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 361,163 Underlying: Common Stock · 3,800 shares Expires 2028-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 22, 2023 previously adopted by the reporting person. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| November 06, 2023 Filed Nov 7, 2023 18:19 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | SaleCommon Stock | 7,449 | $12.03 | $89,610.73 |
DisclosureSEC source: 0000950170-23-060499 · ownership.xml · nonDerivative · entry 2 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 177,291 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 22, 2023 previously adopted by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 06, 2023 Filed Nov 7, 2023 18:19 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | Exercise / conversionCommon Stock | 3,800 | $2.74 | $10,412.00 |
DisclosureSEC source: 0000950170-23-060499 · ownership.xml · nonDerivative · entry 1 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 184,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 22, 2023 previously adopted by the reporting person. Read SEC document |
| October 30, 2023 Filed Nov 1, 2023 18:21 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | SaleCommon Stock | 9,586 | $6.83 | $65,478.13 |
DisclosureSEC source: 0000950170-23-057640 · ownership.xml · nonDerivative · entry 1 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,940 F1 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.80 to $7.345, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 19, 2023 Filed Jan 23, 2023 18:35 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 187,500 | Not disclosed Strike: $10.18 | Not disclosed |
DisclosureSEC source: 0000899243-23-002434 · doc4.xml · derivative · entry 3 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,500 Underlying: Common Stock · 187,500 shares Expires 2033-01-18 F3 · price: The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of January 19, 2023 with the remainder vesting thereafter pro-rata in 36 monthly installments. F3 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of January 19, 2023 with the remainder vesting thereafter pro-rata in 36 monthly installments. Read SEC document |
| January 19, 2023 Filed Jan 23, 2023 18:35 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantCommon Stock | 121,875 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-002434 · doc4.xml · nonDerivative · entry 1 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,526 F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on the one year anniversary of the date of grant. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 20:37 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | SaleCommon Stock | 5,706 | $12.46 | $71,081.92 |
DisclosureSEC source: 0000899243-22-034836 · doc4.xml · nonDerivative · entry 1 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,651 F1 · kind: The sales reported represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.45 to $12.645, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 02, 2021 Filed Nov 2, 2021 16:13 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | ConversionSeries A-2 Preferred Stock · Derivative | 1,510 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-042362 · doc4.xml · derivative · entry 4 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · By EdIP Revocable Trust Disclosed balance after: 0 Underlying: Common Stock · 1,510 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 and Series A-2 Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021. F1 · price: The Series A-1 and Series A-2 Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021. F1 · derivative.exercise_date: The Series A-1 and Series A-2 Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021. F1 · derivative.expiration_date: The Series A-1 and Series A-2 Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021. F2 · ownership.nature: The shares are held by the Elisabet de los Pinos Revocable Trust U/D/T dated April 8, 2016, of which the Reporting Person is a trustee. Read SEC document |
| November 02, 2021 Filed Nov 2, 2021 16:13 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | ConversionSeries A-1 Preferred Stock · Derivative | 3,042 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-042362 · doc4.xml · derivative · entry 3 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · By EdIP Revocable Trust Disclosed balance after: 0 Underlying: Common Stock · 3,042 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 and Series A-2 Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021. F1 · price: The Series A-1 and Series A-2 Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021. F1 · derivative.exercise_date: The Series A-1 and Series A-2 Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021. F1 · derivative.expiration_date: The Series A-1 and Series A-2 Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021. F2 · ownership.nature: The shares are held by the Elisabet de los Pinos Revocable Trust U/D/T dated April 8, 2016, of which the Reporting Person is a trustee. Read SEC document |
| November 02, 2021 Filed Nov 2, 2021 16:13 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | ConversionCommon Stock | 4,552 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-042362 · doc4.xml · nonDerivative · entry 2 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · By EdIP Revocable Trust Disclosed balance after: 131,412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The Series A-1 and Series A-2 Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021. F2 · ownership.nature: The shares are held by the Elisabet de los Pinos Revocable Trust U/D/T dated April 8, 2016, of which the Reporting Person is a trustee. Read SEC document |
| October 28, 2021 Filed Oct 29, 2021 19:28 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 318,750 | Not disclosed Strike: $14.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-042090 · doc4.xml · derivative · entry 3 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,750 Underlying: Common stock · 318,750 shares Expires 2031-10-27 F3 · price: The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of October 28, 2021 with the remainder vesting thereafter pro-rata in 36 monthly installments. F3 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of October 28, 2021 with the remainder vesting thereafter pro-rata in 36 monthly installments. Read SEC document |
| October 28, 2021 Filed Oct 29, 2021 19:28 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantCommon Stock | 74,357 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-042090 · doc4.xml · nonDerivative · entry 1 de los Pinos Elisabet · CIK 0001889633 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,357 F1 · shares: These shares were acquired pursuant to a restricted stock unit award under the Company's 2021 Stock Option and Incentive Plan. Each restricted stock unit represents the right to receive one share of the Company's common stock. These restricted stock units vest in four substantially equal annual installments beginning on the one year anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.